

**Commissioner for Patents** United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 **EAST HANOVER NJ 07936-1080** 

COPY MAILED

JUL 1 4 2006

OFFICE OF PETITIONS

In re Application of

Amlot, et al.

Application No. 09/770,002

Filed: January 25, 2001

Attorney Docket No. 4-30583A

For: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF RHEUMATOID

ARTHRITIS OR SKIN DISEASES

ON PETITION

This is a decision on the petition under 37 CFR 1.137(b), filed on May 19, 2006 to revive the above-identified application.

This application became abandoned for failure to timely file a follow-up submission within two months of the mail date of the June 2, 2004 decision on petition, which entered applicants' Notice of Appeal. Accordingly, this application became abandoned on August 3, 2004. The filing of the present petition precedes the mailing of A Notice of Abandonment.

Applicants have submitted a RCE and required fee and a request to consider the amendment filed on October 28, 2003 as the follow-up submission to the Notice of Appeal, an acceptable statement of the unintentional nature of the delay in filing a follow-up submission to the Notice of Appeal, and the petition fee.

The petition is **GRANTED**.

After the mailing of this decision the application will be forwarded to Technology Center AU 1644 for consideration of the RCE filed on May 19, 2006.

Telephone inquiries pertaining to this decision may be directed to the undersigned at (571) 272-3230.

Shirene Willis Brankley

Shirene Willis Brantley

Senior Petitions Attorney

Office of Petitions